Research programme: inflamation therapeutics - c-a-i-r biosciences

Drug Profile

Research programme: inflamation therapeutics - c-a-i-r biosciences

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator c-a-i-r biosciences
  • Class Small molecules
  • Mechanism of Action 5-lipoxygenase-activating protein modulators; Cyclo-oxygenase 1 modulators; Cyclo-oxygenase 2 modulators; Interleukin 1 beta modulators; Protein kinase inhibitors; Tumour necrosis factor alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Inflammation

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-0 development in Inflammation in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top